Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial

Authors:

Abstract
Recurrence of low-grade bladder cancer is common.1 Intravesical chemotherapy (eg, mitomycin C or epirubicin) administered after transurethral resection of bladder tumor (TURBT) has been shown to be associated with decreased recurrence and is guideline recommended; however, rates use are low.2-4 To that end, the Southwestern Oncology Group (SWOG) S0337 randomized clinical trial (RCT), published in May 2018,5 sought to expand the urologist’s armamentarium by demonstrating the efficacy of post-TURBT intravesical gemcitabine. The authors of the RCT cite the drug’s lower cost, wider availability, and milder toxicity relative to mitomycin C as advantages.5 Whether these findings have increased rates of post-TURBT chemotherapy use is unknown. Additionally, since the trial did not compare gemcitabine directly to other historically used agents, the extent to which gemcitabine has supplanted these drugs is uncertain.